Concert Pharmaceuticals ^{Priced, Nasdaq: CNCE}

Developing drugs via deuterium substitution for spasticity and kidney disease.

Industry: Health Care

First Day Return: +1.3%

CNCE

Developing drugs via deuterium substitution for spasticity and kidney disease.

IPO News for Concert Pharmaceuticals

Feeling cramped? Muscle spasm biotech Flex Pharma sets terms for $60 million IPO 01/20/15
Kidney failure biotech Proteon Therapeutics sets terms for $61 million IPO 10/07/14
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over 02/18/14

IPO Data
IPO Date	02/12/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$84
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Lexington, MA, United States
Founded	2006
Employees at IPO	43
Website www.concertpharma.com

IPO News for Concert Pharmaceuticals

Concert Pharmaceuticals (CNCE) Performance